PCK1 and type 2 diabetes mellitus: We selected rosiglitazone for comparison with ENOblock in T2DM mice due to three considerations: (i) it was previously studied alongside ENOblock in cell based assays, (ii) Rosiglitazone and ENOblock were shown to inhibit Pck-1 expression, which can regulate gluconeogenesis9, 21, (iii) Rosiglitazone produces significant side effects5, 35, which can be compared with ENOblock treatment.